Candel Therapeutics Inc (CADL)
11.56
-1.14
(-8.98%)
USD |
NASDAQ |
May 17, 16:00
11.51
-0.05
(-0.43%)
After-Hours: 20:00
Candel Therapeutics Cash from Financing (Quarterly): -1.255M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -1.255M |
| December 31, 2023 | -0.121M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.036M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.022M |
| March 31, 2022 | 19.92M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00 |
| September 30, 2021 | 71.36M |
| June 30, 2021 | 0.333M |
| March 31, 2021 | 0.112M |
| December 31, 2020 | 0.029M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.46M |
| March 31, 2020 | 0.001M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.255M
Minimum
Mar 2024
71.36M
Maximum
Sep 2021
5.346M
Average
0.001M
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| Allurion Technologies Inc | 0.387M |
| AngioDynamics Inc | 0.694M |
| Eliem Therapeutics Inc | 0.015M |
| Macrogenics Inc | 0.248M |
| GlycoMimetics Inc | 0.0049M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.438M |
| Cash from Investing (Quarterly) | -0.007M |
| Free Cash Flow | -32.19M |
| Free Cash Flow Per Share (Quarterly) | -0.2892 |
| Free Cash Flow Yield | -9.65% |